Abstract
The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9% (free) and 29.85 ± 22.61% (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 327-335 |
| Number of pages | 9 |
| Journal | Journal of Veterinary Pharmacology and Therapeutics |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2007 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- veterinary(all)
Cite this
The bioavailability and disposition kinetics of genistein in cats. / Cave, N. J.; Backus, R. C.; Marks, Stanley L; Klasing, K. C.
In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 30, No. 4, 08.2007, p. 327-335.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The bioavailability and disposition kinetics of genistein in cats
AU - Cave, N. J.
AU - Backus, R. C.
AU - Marks, Stanley L
AU - Klasing, K. C.
PY - 2007/8
Y1 - 2007/8
N2 - The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9% (free) and 29.85 ± 22.61% (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.
AB - The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9% (free) and 29.85 ± 22.61% (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.
UR - http://www.scopus.com/inward/record.url?scp=34347400398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347400398&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2885.2007.00868.x
DO - 10.1111/j.1365-2885.2007.00868.x
M3 - Article
VL - 30
SP - 327
EP - 335
JO - Journal of Veterinary Pharmacology and Therapeutics
JF - Journal of Veterinary Pharmacology and Therapeutics
SN - 0140-7783
IS - 4
ER -